LAUSR

Rationale: Angiogenesis is a key factor for tumor growth and metastasis both in cancer and sarcoma. Endostar, a novel safe and well-tolerated recombinant human endostatin, can suppress the expression of VEGF and the activation of ERK, MAPK, and AKT, and then inhibit tumor progression. Patient concerns: A pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion. Diagnoses: Osteosarcoma with pulmonary metastasis and malignant pleural effusion. Interventions: Considering the physical condition of patient, the patient underwent surgical resection of the right lung lesion after receiving endostar combined with chemotherapy and maintained endostar alone for 47 cycles. Outcomes: The patient obtained pathologic complete remission and had been in progression-free survival up to now. Lessons: Our experience could provide a treatment strategy for pediatric osteosarcoma patients with pulmonary metastasis and malignant pleural effusion.